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THE ROLE OF GLYCOGEN SYNTHASE KINASE-3 AND CAMP RESPONSE 
ELEMENT-BINDING PROTEIN IN THE INDUCTION AND REGULATION OF 
CARDIAC HYPERTROPHY IN NEONATAL RAT VENTRICULAR MYOCYTES 
SEAN MATTHEW SEPULVEDA 
ABSTRACT 
Glycogen synthase kinase-3 (GSK3) is a ubiquitously expressed protein kinase 
with key roles in controlling proliferation, differentiation and survival of a wide 
variety of mammalian cells. In most cells, GSK3 is active in the absence of 
growth factor signaling and acts to inhibit cell proliferation and induce apoptosis. 
In cardiomyocytes, GSK3 plays a novel role as a negative regulator of cardiac 
hypertrophy, and it appears that GSK3 plays a central role as an inhibitor of 
cardiac hypertrophy induced by a variety of stimuli. In the present study, we 
sought to further elucidate the role of GSK3 in cardiomyocyte hypertrophy by 
studying the effects of inhibition of GSK3 in the absence of other hypertrophic 
stimuli. By combining global expression profiling with computational predictions 
and experimental analysis of transcription factor binding sites, we have identified 
hypertrophy-related genes that are controlled directly by GSK3 and have found 
that CREB is a major transcriptional target of GSK3 in cardiomyocytes. In 
addition, we find that inhibition of GSK3 is sufficient to induce the re-expression 
of fetal development genes characteristic of hypertrophy, but not sufficient to 
induce the full hypertrophic phenotype of cardiomyocyte growth.  
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CHAPTER ONE – INTRODUCTION 
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Cardiac hypertrophy (enlargement of the heart) affects approximately 1 in 500 
people or 0.2% of the population according to the American Heart Association. It 
is a normal adaptive response to stress and exercise as well as to conditions 
such as arterial hypertension and other heart disease, but a prolonged response 
can lead to heart failure and sudden death due to the heart overworking itself. 
Generally, it is referred to as left ventricular hypertrophy (LVH), but when the 
magnitude of the phenotype becomes more severe, it is termed hypertrophic 
cardiomyopathy (HCM). At the physiological level, characteristics are the 
thickening of the myocardium (heart muscle), specifically and most commonly the 
septum and ventricular but not the atrial walls. The left ventricle is most 
commonly affected, hence the name. The thickening impedes contractility and 
can in many cases decrease the volume of the left ventricle, making it more 
difficult for the heart to pump less blood through the aorta and to the rest of the 
body. It can also affect proper functionality of the mitral valve, causing backflow 
into the left atrium and creating even more pressure on the left ventricle. At the 
molecular level, the hallmarks are the re-expression of certain fetal genes and an 
increase in cardiomyocyte size and length, protein synthesis, and sarcomere 
organization (Frey and Olson 2003). Currently, the causes are due to genetic 
inheritance, high blood pressure, aging, and very intense exercise, but outside of 
these, they are not well defined. There is also great variability in the phenotype 
even when the cause is the same. It is unclear whether a distinction needs to be 
made among the causes of hypertrophy as there are many molecular pathways 
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by which hypertrophy can come about as reviewed by Frey and Olson, such as 
calcineurin/NFAT signaling, PI3K/Akt/GSK-3/mTOR signaling, G protein-coupled 
receptors, and MAPK signaling. Understanding the molecular underpinnings of 
the various stimuli that cause and/or contribute to cardiac hypertrophy is crucial 
to developing effective treatments. 
 
Glycogen synthase kinase-3 (GSK3) is a serine/threonine kinase that was first 
discovered in 1980 in the context of glycogen synthesis regulation (Embi et al. 
1980). Since then, much has been discovered about its ubiquity in the cell. It has 
been implicated in various diseases, such as cancer (Manoukian and Woodgett 
2002), Alzheimer’s (Grimes and Jope 2001), and diabetes (Frame and Cohen 
2001, Frame et al. 2001). Its importance has been demonstrated in various 
pathways, such as apoptosis (Terragni et al. 2011), cellular structure, growth, 
motility, as well as proliferation, development, differentiation, and survival. Two 
unique features of GSK3 are that it is active in the absence of growth factors 
(Tullai et al. 2011a) and that it strongly prefers its substrates to be 
phosphorylated prior to binding and catalyzing its own phosphorylation reaction. 
This prior phosphorylation state is called priming. The consensus sequence for 
substrate recognition is Ser/ThrXXXpSer/pThr (ter Haar et al. 2001, Sutherland 
2011). GSK3 activity decreases dramatically if its substrate has not received this 
priming phosphorylation, termed the P+4 position (ter Haar et al. 2001, 
Sutherland 2011). GSK3 has two isoforms (α and β) and consists of two 
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domains, one consisting of mostly β-strands to form a β-barrel and the other 
consisting of α-helices. Substrate binding occurs at the point where these two 
domains join together. Other important features in this region are the hinge, 
glycine rich loop, and activation loop. The positively charged residues Arg96, 
Arg180, and Lys205 form a pocket for binding the negatively charged phosphate 
of the primed substrate. Substrate binding and fitting into this pocket causes the 
enzyme to undergo a conformational change that allows it to carry out 
phosphorylation. In short, the substrate binding site has been designed to bind to 
a primed substrate. GSK3 is regulated by an inhibitory phosphorylation on Ser9 
of GSK3α and Ser 21 of GSK3β; conversely GSK3 activity is enhanced by 
phosphorylation of Tyr279 on GSK3α and Tyr216 on GSK3β (Jope and Johnson 
2004). GSK3 is best known for its involvement in apoptosis, a failsafe measure 
and one of the most important functions in the cell. Impairment with this cellular 
protocol can lead to cancer due to defective cells not being properly eliminated 
and allowed to proliferate. One of the major signaling pathways in the cell is the 
phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B)/GSK3 pathway. PI3K 
consists of a p110 catalytic domain and p85 regulatory domain (Duronio 2008). 
PI3K is activated by various external stimuli, including insulin and growth factors 
by way of IGF-1, G protein-coupled receptors (GPCRs), and α/β adrenergic 
receptors, all of which are receptor tyrosine kinases. When PI3K is activated, it 
phosphorylates lipids on the plasma membrane (PIP2 → PIP3), which recruits 
other proteins such Akt/PKB. Akt/PKB is phosphorylated by PI3K and other 
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kinases to become fully activated. As mentioned above, GSK3 is active in 
quiescent cells. When certain stimuli are received such as from growth factors, 
the PI3K pathway is turned on, causing Akt/PKB to phosphorylate and turn off 
GSK3. The genes that were being repressed by GSK3 are now free to be 
transcribed and translated. 
 
There are so many purported targets of GSK3 that criteria were set to properly 
establish the real ones (Sutherland 2011). cAMP response element-binding 
protein (CREB) is one of these many targets (Tullai et al. 2007a) and is typically 
associated with the PKA pathway. CREB is a transcription factor that binds the 
CRE sequence of different promoters and is constitutively sitting on its target 
promoters. Protein kinase A (PKA) activates CREB through a serine-133 
phosphorylation (Chrivia et al. 1993, Kreusser and Backs 2014), which is 
required for the recruitment of CREB binding protein (CBP) and activation of 
transcription. PKA is activated by the induction of cyclic AMP (cAMP) when G 
protein-coupled receptor signaling stimulates adenylyl cyclase. GSK3 enters the 
nucleus by way of its nuclear localization signal (Meares and Jope 2007) to 
phosphorylate CREB although there is controversy in the literature about whether 
the function of the Ser-129 phosphorylation by GSK3 is inhibitory or enhances 
CREB activation (Grimes and Jope 2001). 
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Because of its widespread influence, GSK3 is not a useful therapeutic target 
directly because of the large number of potential side effects that could occur 
upon treatment. However, it can be used to narrow down the number of genes 
under its control as related to specific contexts such as cardiac hypertrophy. 
These genes, in turn, would make better therapeutic targets as they are further 
downstream in the signaling cascades. The bottom line is that GSK3 has been 
implicated as a negative regulator of cardiac hypertrophy (Haq et al. 2000) and 
CREB has also been linked to cardiac pathophysiology as a major regulator of 
cardiac gene expression (Markou et al. 2004).  
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CHAPTER TWO – DATA 
This chapter consists of a paper that has been submitted for publication and on 
which I am an author. The other authors are Tullai JW, Moss ME, Cooper GM, 
Naya FJ, and Brennan JF. I made contributions to Figures 1, 2, 3C, 4A and 
Supplementary Tables 1, 2, 3. 
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Because GSK3 is simultaneously a positive regulator of apoptosis and a negative 
regulator of cardiac hypertrophy, it became necessary to elucidate the targets of 
GSK3 as related to cardiac hypertrophy versus apoptosis. In doing so, we also 
hoped to uncover novel drug targets for the treatment of this potentially fatal 
condition. We approached this problem by way of microarray analysis and global 
gene expression profiling in order to see the big picture. From studies of the PI3K 
pathway, it is known that GSK3 is regulated by PI3K through activation of Akt 
and subsequent phosphorylation of GSK3 by Akt. We treated neonatal rat 
ventricular myocytes (NRVMs) with phenylephrine to induce cardiac hypertrophy 
and also with the PI3K inhibitor LY294002 prior to phenylephrine treatment to 
ascertain which genes were linked to cardiac hypertrophy and under the 
regulation of GSK3. What we discovered was that there were very few genes that 
were induced by phenylephrine and sensitive to LY294002 treatment (data not 
shown). This suggested that GSK3 is regulated differently in heart cells. Thus, 
we repeated the microarray with the phenylephrine treatment as well as with the 
GSK3 inhibitor SB216763 prior to phenylephrine treatment. This global gene 
expression profiling approach revealed well over 100 genes that were induced by 
phenylephrine and inhibited by GSK3, which we verified by RT-PCR. 
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METHODS 
Cardiomyocyte Isolation, Culture and Treatments 
Primary cardiomyocytes were isolated from 1-2 day old neonatal rats (Sprague-
Dawley, Charles River Laboratories) as described previously (Calderone et al. 
1998). Neonatal rats were sacrificed by decapitation and hearts removed. 
Ventricular tissue was incubated overnight with 0.1% trypsin (Sigma) in HBSS 
(Invitrogen). Ventricular myocytes were then recovered by successive 0.1% 
collagenase (Worthington) digestions. Following two pre-platings to eliminate 
fibroblasts, cardiomyocytes were plated on gelatin-coated plates and allowed to 
recover overnight in 10% fetal bovine serum (FBS, Hyclone) in DMEM, and then 
switched to DMEM containing 0.5X Nutridoma (Roche) and 0.1 mM 5-
bromodeoxyuridine (Sigma) for 24 hours prior to treatments. Cells were treated in 
vitro with phenylephrine or isoprenaline for 1 hour, and with 10 µM SB-216763 
(Enzo/BioMol), 10 µM BIO ((2’Z,3’E)-6-Bromoindirubin-3’-oxime) (Enzo/BioMol), 
25 µM Rp-CAMPs (Santa Cruz Biotechnology), 10 µM U0126 (Millipore/Upstate), 
20 µM KN-62 (EMD/Millipore), or the corresponding DMSO control for the times 
indicated in the text. All experimental procedures were conducted with approval 
from the Institutional Animal Care and Use Committee of Boston University. 
 
Microarray Analysis 
Microarrays were performed on three independent cultures of cardiomyocytes. 
Total RNA was isolated using Trizol (Invitrogen). Following the ethanol 
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precipitation step, RNA was applied to an RNeasy column (Qiagen) as per the 
manufacturer’s procedure. RNA quality was confirmed using an Agilent 
bioanalyzer before analysis on Affymetrix Rat Gene 1.0ST microarrays. 
Microarray sample labeling, hybridization, scanning and data analysis were 
performed by the Boston University Microarray Core Facility. 
 
Gene Ontology Analysis 
Overrepresentation of Gene Ontology (GO) terms was determined using the 
Data Base for Annotation, Visualization and Integrated Discovery (DAVID) 
Version 6.7 (Huang et al. 2009, Dennis et al. 2003). The frequency of GO terms 
in a test gene set was compared to the entire rat genome. The DAVID functional 
annotation clustering tool identified overrepresented GO terms that co-associated 
together. 
 
Immunoblots 
Whole cell lysates were electrophoresed in 10% SDS-polyacrylamide gels 
(Laemmli 1970) and transferred to either nitrocellulose or PVDF membranes. 
Membranes were then incubated with antibodies to CREB (Cell Signaling 9197), 
CREB phospho-serine 133 (Cell Signaling 4276) or β-actin (Sigma A1978). 
Immunoblots were then incubated with a horseradish peroxidase secondary 
antibody (Bio-Rad) followed by visualization using chemiluminescence and 
exposure to autoradiography film. 
	  	  
11	  
 
Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated using Trizol (Invitrogen) using the manufacturer’s 
procedure. RNA was used in quantitative real-time reverse transcription 
polymerase chain reactions (RT-PCR) as previously described (Tullai et al. 
2007a, Tullai et al. 2011b), except using a minimum of 0.75 µg of total RNA in 
the reverse transcription reaction. Briefly, reverse transcription reactions on total 
RNA were performed using SYBR green RT-PCR reagents with random 
hexamer primers (Applied Biosystems). RT-PCR was performed using an ABI 
Prism 7900HT Sequence Detection System with 1 µl of the RT reaction, 100 nM 
PCR primers (see Supplementary Table 1 for RT-PCR primer sequences) and 
SYBR Green PCR Master Mix in 5 µl reactions. Triplicate reactions were 
analyzed using Sequence Detection System software (v2.2.2), calculating 
relative expression levels with GAPDH as the normalization transcript (ΔΔCT). 
 
Transcription Factor Binding Site Analysis 
Determination of statistically overrepresented transcription factor binding sites in 
the upstream regions of the GSK-3 repressed genes as compared to a 
background set was conducted as previously described (Tullai et al. 2007a, Tullai 
et al. 2004, Tullai et al. 2007b). The background set consisted of 501 genes that 
were expressed, but not induced in the presence of phenylephrine on the 
microarrays (log2 fold change >-0.002, <0.005). 1-, 3-, and 5-kb upstream 
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regions relative to the transcription start sites in rat and in the human orthologous 
sequences were analyzed using the MATCH algorithm under MinSUM thresholds 
with transcription factor binding site matrices from TRANSFAC v12.1. MULTIZ 
alignments of the orthologs were obtained from the University of Santa Cruz 
Genome Browser (rn4/November 2004, hg18/March 2006), which contained 12 
of the 14 GSK-3 repressed genes. Binding site matrices that hit less than 50% of 
the test group and/or more that 1 predicted site per kb in the background set 
were excluded from further analysis. Permutation p-values were false discovery 
rate (FDR) corrected (Benjamini and Hochberg 1995). 
 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitations (ChIPs) were performed as previously 
described (Tullai et al. 2007a) using 5 µg of anti-CREB-1 (Santa Cruz sc-186), 5 
µg of anti-CBP (Santa Cruz sc-369) or 5 µg of normal rabbit IgG as a control 
(Santa Cruz, sc-2027). Salmon sperm DNA/Protein A agarose (Upstate 
Biotechnology) bead slurry (50%) immunoprecipitates were successively washed 
in low salt, high salt, and lithium chloride buffers before being washed twice with 
1X TE (10 mM Tris-HCl, 1 mM EDTA pH 8.0). Immunoprecipitated chromatin 
was quantified with RT-PCR (see Supplementary Table 2 for precise locations of 
sites, primers and primer sequences). MYOG was used as the negative control 
for all ChIPs. 
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Protein Synthesis Assay 
Cardiomyocytes were plated at 2x105 cells per well in gelatin coated 48-well 
plates, allowed to recover overnight and then switched to DMEM containing 0.5X 
Nutridoma and 0.1 mM 5-bromodeoxyuridine for 24 hours as described above. 
The cells were then switched to the same media containing 35S-methionine/35S-
cysteine (EasyTag Express Protein Labeling Mix, [35S]-, Perkin Elmer) to a final 
concentration of 10 µCi/ml. After treatments indicated in the text, cells were 
rinsed once with cold PBS, harvested in 0.5 ml cold lysis buffer (PBS pH 7.4, 1% 
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS), and then supplemented 
with 200 µl of 1 mg/ml BSA on ice. 1 ml of 10% TCA was added and the 
suspensions were incubated on ice for 30 minutes. Samples were then filtered 
through glass microfiber filters (Whatman 1822 025), and washed with 4x1 ml of 
10% cold TCA and then with 1 ml 70% cold ethanol. The radioactivity on the 
filters was quantified by liquid scintillation counting. 
 
RESULTS 
Identification of GSK3 Regulated Genes 
We initially sought to identify a set of genes induced in cardiomyocytes in 
response to hypertrophy-inducing agents, and then to determine whether a 
subset of these genes was regulated by GSK3. We began with global expression 
profiling of cardiomyocyte cultures in response to acute treatment with 
phenylephrine, an α1-adrenergic receptor agonist and hypertrophy-inducing 
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agent. Microarray hybridizations were performed with RNA isolated from vehicle-
treated control and phenylephrine-treated cardiomyocytes. In order to assess the 
initial transcriptional response to a hypertrophic stimulus, cardiomyocytes were 
treated with phenylephrine for one hour. This resulted in the up-regulation of 131 
genes (>1.7 fold, p<0.001) (Supplementary Table 3). Additionally, the microarray 
data revealed 12 down-regulated genes (>1.7-fold, p<0.01). In addition to 10 
protein coding genes, the down-regulation of miR-133a and miR-1 was observed. 
It has been previously shown that expression of both these miRNAs is decreased 
upon induction of hypertrophy by various agents, and inhibition (targeted 
knockdown) of either will induce hypertrophy (Care et al. 2007). 
 
The Gene Ontology (GO) database was used to characterize the functions of the 
genes up-regulated by phenylephrine. The frequency of GO terms of the 131 up-
regulated genes was compared to the frequencies in the entire rat genome. The 
ten most significantly enriched Biological Process GO terms are shown in Table 
1. These genes were enriched in GO categories related to regulation of 
transcription, RNA metabolism and positive regulation of biosynthetic processes. 
All of these categories were consistent with the induction of hypertrophic growth 
signaling. 
 
In order to determine whether GSK3 was involved in regulation of the genes 
induced by phenylephrine, we tested the effect of direct inhibition of GSK3 on 
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expression of 104 of the 131 phenylephrine-induced genes. Cardiomyocytes 
were treated either with phenylephrine or with the GSK3 inhibitor SB-216763 and 
gene expression changes were quantitated by RT-PCR. In addition to validating 
the microarray results (see Supplementary Table 3), we found that 14 of the 104 
PE-induced genes tested were up-regulated greater than 1.7-fold by direct 
inhibition of GSK3 alone: ARC, B3GNT, BHLHB2, CCL7, CXCR7, EGR1, EGR2, 
FOS, LIF, NR4A1, NR4A3, SNAI1, SNF1LK and ZFP36L2 (Figure 1A, note log2 
scale). This indicated that GSK3 is actively inhibiting expression of these genes 
in the absence of a hypertrophic signal and that inhibition of GSK3 alone is 
sufficient to induce their expression. Induction of at least half of these genes by 
direct GSK3 inhibition was comparable to that of PE, suggesting that GSK3 plays 
a major role in these genes’ regulation. 
 
The functions of the genes induced by inhibition of GSK3 are summarized in 
Figure 1B. Seven of the genes encode transcription factors (BHLHB2, EGR1, 
EGR2, FOS, NR4A1, NR4A2, SNAI1), and are general immediate early genes 
(Tullai et al. 2004, Herschman 1991, Veltmaat et al. 2000, Winkles 1998). In 
addition, ZFP36L2, also known as BRF2, encodes an RNA binding protein that 
targets ARE-containing mRNAs for rapid degradation (Sanduja et al. 2011). 
Interestingly, SNF1LK (also known as SIK1) encodes a serine/threonine kinase 
that modulates transcription involved in cardiac muscle differentiation (Romito et 
al. 2010). Three genes encoded cytokines and receptors (CCL7, CXCR7, LIF). 
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The functions of these genes indicated that they are predominantly involved in 
cell signaling and transcriptional regulation. 
 
CREB mediates gene regulation downstream of GSK3 
Co-regulated genes often share common transcription factor binding sites. 
Therefore, computational analysis was used to predict transcription factor binding 
sites that are overrepresented upstream of the GSK3 regulated genes. We 
analyzed regions of 1-, 3- and 5-kb upstream of the transcription start sites of 12 
genes (upstream sequence information for 2 genes was not available on the 
UCSD database). This analysis identified binding sites for several transcription 
factors, including CREB, AP-1, NFκB, FoxO, MEF2 and NFAT, which were 
statistically overrepresented in rat and human (see Supplementary Table 4). 
CREB was the most significantly overrepresented transcription factor for the 
group of GSK3 regulated genes (p<10-5). Moreover, CREB cis-elements were 
predicted upstream of all 12 genes analyzed. 
 
CREB has previously been shown to be a regulator of hypertrophy, as well as a 
GSK3 substrate (Fiol et al. 1994), making CREB a potential mediator of GSK3 
regulated transcription. We therefore sought to confirm the computationally-
predicted CREB binding sites by chromatin immunoprecipitation (ChIP) 
experiments in NRVM cells. CREB has been shown to occupy its binding sites 
constitutively (Conkright et al. 2003), so we compared immunoprecipitation with a 
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CREB-specific antibody to a non-specific IgG control antibody. We found that 
CREB binds to predicted sites in the upstream sequences of 8 of the 12 genes 
tested (Figure 2A). Note that some genes have multiple binding sites plotted, and 
not all sites were positive for every gene. 
 
CREB is activated by recruitment of its coactivator, CREB binding protein, CBP. 
Phosphorylation of CREB on serine 133 provides a docking site for CBP, leading 
to transcriptional activation of CREB target genes (Chrivia et al. 1993, Gonzalez 
and Montminy 1989). GSK3 inhibits CREB activation (Tullai et al. 2007a, Fiol et 
al. 1994, Bullock and Habener 1998, Grimes and Jope 2001, Liang and Chuang 
2006, Martin et al. 2005), so we conducted CBP ChIP assays to determine 
whether inhibition of GSK-3 resulted in the recruitment of CBP to CREB binding 
sites (Figure 2B). In response to inhibition of GSK3 with either SB-21673 or the 
distinct GSK3 inhibitor BIO, CBP was recruited to 7 of the 8 genes that had 
CREB present: NR4A1, NR4A3, EGR2, FOS, BHLHB2, SNF1LK and ZFP36L2 
(Figure 2B). Thus, inhibition of GSK3 resulted in CREB activation and CBP 
recruitment in cardiomyocytes. 
 
We further determined the effect of GSK3 inhibition on the activating 
phosphorylation of CREB serine 133. As expected, stimulation of cardiomyocytes 
with phenylephrine caused an increase in CREB phosphorylation on serine 133 
by way of the protein kinases PKA and MSK1 (which is activated by ERK and 
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p38 MAP kinase) downstream of the Gq coupled α1-adrenergic receptor (Figure 
3A, Markou et al. 2004). Interestingly, direct inhibition of GSK3 with SB-216763 
also resulted in increased phosphorylation of CREB on serine 133, indicating that 
GSK3 inhibits CREB phosphorylation in unstimulated cardiomyocytes (Figure 
3A). 
 
The finding that inhibition of GSK3 increased CREB phosphorylation on serine 
133 implies that one or more kinases phosphorylating this site are active in 
unstimulated cardiomyocytes. In addition to PKA and the MSK protein kinases, 
casein kinase II (CKII) and RSK (which is activated by ERK, Xing et al. 1996) are 
capable of phosphorylating CREB on serine 133. Therefore, we tested which 
kinase was responsible for phosphorylating CREB on serine 133 upon inhibition 
of GSK3 in unstimulated cardiomyocytes. Cardiomyocytes were treated with SB-
216763 alone, or preincubated with inhibitors of PKA, CKII and MEK individually 
(Figure 3B). Pretreatment with KN-62, a CKII inhibitor, inhibited CREB serine 133 
phosphorylation by 64% as compared to cells treated with SB-216763 alone 
(Figure 3B). Pretreatment with Rp-cAMPs (a PKA inhibitor) resulted in only a 
modest 33% inhibition of serine 133 phosphorylation. Finally, pretreatment with 
U0126, a MEK inhibitor, resulted in a 54% inhibition. These data suggest that 
CKII and MSK or RSK are the primary kinases responsible for CREB serine 133 
phosphorylation in unstimulated cardiomyocytes and that inhibition of GSK3 
increases the extent of CREB phosphorylation by these kinases. 
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To test if these kinases are, in turn, responsible for gene induction following 
GSK3 inhibition, cardiomyocytes were again treated with SB-216763 alone, or 
preincubated with KN-62 or U0126, and gene induction analyzed by RT-PCR 
(Figure 3C). The inductions of FOS, NR4A1, and NR4A3, were significantly 
blocked upon pre-treatment with either KN-62 or U0126, suggesting that CKII 
and MSK or RSK contribute to activation of CREB and induction of CREB target 
genes in unstimulated cardiomyocytes. 
 
Inhibition of GSK3 Alone Induces a Partial Hypertrophic Phenotype 
We next wished to explore whether inhibition of GSK3 alone was sufficient to 
induce hypertrophy in cardiomyocytes. Re-expression of fetal developmental 
genes is a hallmark of the onset of hypertrophy, with upregulation of these genes 
typically seen 24 hours after hypertrophic stimulation. Transcriptional markers of 
hypertrophy (ANP, BMP, and ACTA) were induced 24 hours after treatment with 
phenylephrine, as well as with two other well-established hypertrophy inducers, 
isoprenaline and serum (Figure 4A). Direct inhibition of GSK3 by treatment with 
SB-216763 likewise induced ANP, BMP, and ACTA at 24 hours (Figure 4A), 
indicating that inhibition of GSK3 was sufficient to induce the transcriptional 
reprogramming characteristic of cardiomyocyte hypertrophy. 
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Assays of protein synthesis were then conducted (Figure 4B) to assess whether 
GSK3 inhibition alone was able to increase cell growth. Phenylephrine, 
isoprenaline and serum increased protein synthesis over 48 hours, as expected. 
However, the GSK3 inhibitor did not increase protein synthesis, instead resulting 
in a decrease in protein synthesis over a 48 period. Thus, inhibiting GSK3 alone 
is sufficient to induce a partial hypertrophic phenotype indicated by transcriptional 
reprogramming, but not the full hypertrophic phenotype associated with cell 
growth and increased protein synthesis. 
 
DISCUSSION 
GSK3 is well established as a negative regulator of cardiomyocyte hypertrophy 
induced by a variety of stimuli. In the present study, we have investigated the role 
of GSK3 in controlling the growth of unstimulated cardiomyocytes by 
characterizing the effects of inhibition of GSK3 in the absence of hypertrophic 
stimulation. Inhibition of GSK3 was sufficient to induce transcription of about 15% 
of the genes induced in cardiomyocytes in response to the hypertrophy-inducing 
agent, phenylephrine. Half of the immediate-early genes induced by inhibition of 
GSK3 encoded transcription factors (BHLHB2, EGR1, EGR2, FOS, NR4A1, 
NR4A2, SNAI1), suggesting that GSK3 was potentially playing a major role as a 
transcriptional regulator not only for this class of immediate early genes, but also 
in the subsequent induction of secondary response genes. Another gene induced 
by inhibition of GSK3, BRF2, encodes an RNA binding protein targeting ARE-
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containing mRNAs for rapid degradation (Sanduja et al. 2011). This suggests 
that GSK3 may be involved in the concomitant initiation of a tightly regulated 
mechanism of mRNA turnover. Other genes regulated by GSK3 included 
cytokines and receptors as well as the protein kinase SNF1LK, which modulates 
transcription involved in cardiac muscle differentiation (Romito et al. 2010). 
Consistent with the induction of these transcription factors and signaling 
molecules, inhibition of GSK3 was also sufficient to induce the transcriptional 
reprogramming of cardiomyocytes, as indicated by the characteristic re-
expression of fetal development genes 24 hours after hypertrophic stimulation. 
Thus, the activity of GSK3 in unstimulated cardiomyocytes plays a significant role 
in suppressing the transcriptional program characteristic of hypertrophy. 
 
Computational analysis identified binding sites for several transcription factors, 
including CREB, AP-1, NFκB, Forkhead, MEF2 and NFAT, as being 
overrepresented and conserved in rat and human sequences upstream of the 
GSK3-regulated genes. CREB was the most highly overrepresented of these 
factors, consistent with previous studies showing that CREB is a major regulator 
of cardiomyocyte hypertrophy (Hardt and Sadoshima 2004) and is similarly 
regulated by GSK3 in quiescent human glioblastoma cells arrested by growth 
factor starvation (Tullai et al. 2007a). Computational predictions of CREB binding 
sites upstream of the majority of GSK3-regulated genes were confirmed by 
chromatin immunoprecipitation. Moreover, inhibition of GSK3 led to the 
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recruitment of CBP, the co-activator that ultimately stimulates transcription of 
CREB target genes. 
 
We next examined how inhibition of GSK3 might be inducing CREB activation 
and CBP recruitment in cardiomyocytes. CREB is activated by phosphorylation of 
serine 133, which provides a docking site for CBP (Chrivia et al. 1993, Gonzalez 
and Montminy 1989). GSK3 phosphorylates CREB on serine 129 (Fiol et al. 
1994) and is well established as a negative regulator of CREB activation (Bullock 
and Habener 1998, Grimes and Jope 2001, Liang and Chuang 2006, Martin et al. 
2005). We found that inhibition of GSK3 resulted in an increase in serine 133 
phosphorylation of CREB, consistent with the recruitment of CBP to CREB target 
genes. We further found that the phosphorylation of CREB serine 133 was 
catalyzed by both CKII and MSK or RSK protein kinases following inhibition of 
GSK3. It thus appears that GSK3 inhibits the activating phosphorylation of CREB 
and that inhibition of GSK3 increases serine 133 phosphorylation catalyzed by 
these protein kinases in cardiomyocytes. 
 
We finally examined whether inhibiting GSK3 was sufficient to induce 
hypertrophy in cardiomyocytes. The induction of the transcriptional markers of 
fetal gene re-expression (ANP, BMP, and ACTA) 24 hours after inhibition of 
GSK3 was similar to their induction by other hypertrophic agents (phenylephrine, 
serum and isoprenaline), indicating that inhibition of GSK3 was sufficient to lead 
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to the transcriptional reprogramming of cardiomyocytes. However, protein 
synthesis assays revealed that solely inhibiting GSK3 was not sufficient to cause 
an increase in protein synthesis over 48 hours, as was induced in response to 
phenylephrine, serum and isoprenaline. Indeed, rather than increasing protein 
synthesis, inhibition of GSK3 reduced protein synthesis over 48 hours in 
cardiomyocytes. Although GSK3 can inhibit protein synthesis by phosphorylation 
of eIF2B (Welsh et al. 1998, Pavitt 2005, Wang et al. 2001), this finding is 
consistent with recent reports that GSK3 can also stimulate protein synthesis by 
activating p70 S6 kinase (Shin et al. 2011) or inhibiting AMPK (Suzuki et al. 
2013). Our results are also consistent with previous studies suggesting that 
solely inhibiting GSK3 only increased myocyte length, whereas full induction of 
hypertrophy with phenylephrine increased both length and width (Markou et al. 
2008). It thus appears that inhibition of GSK3 is sufficient to induce the 
transcriptional reprogramming characteristic of hypertrophy but that parallel 
inputs from other signaling pathways are required to increase protein synthesis 
and cell growth. 
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FIGURES AND TABLES 
Term % of gene set p-value 
GO:0045449~regulation of transcription 36.5 1.63x10-8 
GO:0051252~regulation of RNA metabolic 
process 30.8 2.86x10
-7 
GO:0006355~regulation of transcription, DNA-
dependent 29.8 7.86x10
-7 
GO:0010557~positive regulation of 
macromolecule biosynthetic process 21.2 2.96x10
-6 
GO:0045893~positive regulation of transcription, 
DNA-dependent 18.3 3.98x10
-6 
GO:0051254~positive regulation of RNA 
metabolic process 18.3 4.57x10
-6 
GO:0045941~positive regulation of transcription 19.2 7.42x10-6 
GO:0031328~positive regulation of cellular 
biosynthetic process 21.2 7.81x10
-6 
GO:0045935~positive regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid 
metabolic process 
20.2 1.03x10-5 
GO:0009891~positive regulation of biosynthetic 
process 21.2 1.07x10
-5 
 
Table 1. Functional analysis of phenylephrine-induced genes. Gene ontology 
analysis using the DAVID Bioinformatics database was conducted on the gene 
set that was induced upon phenylephrine treatment for 1 hour. Shown are the top 
ten GO terms that were overrepresented in this gene set. 
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Figure 1. Gene induction by inhibition of GSK-3. A. Cardiomyocytes were 
incubated in DMEM containing 0.5X Nutridoma for 24 hours after plating. Cells 
were then treated with phenylephrine or SB-216763 for 1 hour, and were 
compared to untreated or DMSO vehicle controls, respectively. Total RNA was 
isolated and analyzed using quantitative real-time reverse transcription RT-PCR. 
Data are means of three independent experiments ± S.E. B. Functional 
categorization of SB-216763 induced genes. 
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Figure 2. CREB binding and CBP recruitment. A. Cardiomyocytes were plated in 
DMEM containing 0.5X Nutridoma for 24 hours. Chromatin fragments were 
immunoprecipitated with anti-CREB1 antibody (grey bars) or normal IgG (white 
bars). Data are means of three independent experiments ± SE. Positive CREB 
binding sites (>2 fold enrichment as compared to IgG, and >2 fold as compared 
to the negative control MYOG) are indicated by asterisks. B. Cardiomyocytes in 
DMEM/0.5X Nutridoma were treated with SB-216763 (black bars), BIO (grey 
bars), or DMSO (white bars) for 1 hour. Chromatin fragments were 
immunoprecipitated with anti-CBP antibody. Only CREB-positive sites were 
probed as per Figure 2A. Data are means of at least three independent 
experiments ± SE. 
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Figure 3. CREB phosphorylation. A. Cardiomyocytes were plated in DMEM/0.5X 
Nutridoma for 24 hours, and then treated with phenylephrine (PE), SB-216763 
(SB-2), DMSO control, or left untreated (NT). Cell extracts were analyzed by 
immunoblotting with antibodies against CREB, CREB phospho-serine 133, and 
β-actin. Data are representative from at least 3 independent experiments. Panels 
were taken from different parts of the same autoradiography film, so they may be 
directly compared. B. Cardiomyocytes were treated with KN-62, Rp-cAMPs or 
U0126 for 30 minutes prior to SB-216763 treatment for 1 hour. C. 
Cardiomyocytes were plated in DMEM/0.5X Nutridoma for 24 hours, and then 
treated with DMSO control (black bars) KN-62 (white bars) or U0126 (grey bars) 
prior to SB-216763 treatment for 1 hour. Total RNA was isolated and analyzed 
using quantitative real-time reverse transcription RT-PCR. Data are means of two 
independent experiments ± S.E. 
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Figure 4. Re-expression of fetal developmental genes and protein synthesis. A. 
Cardiomyocytes were plated in DMEM/0.5X Nutridoma for 24 hours, and then 
treated with phenylephrine (PE), isoprenaline (ISO), 20% serum or SB-216763 
for 24 hours. Total RNA was isolated and analyzed using quantitative real-time 
reverse transcription RT-PCR. Data are means of 3 independent experiments     
± S.E. B. Cardiomyocytes in DMEM/0.5X Nutridoma were treated with 
phenylephrine, isoprenaline, 20% serum or SB-216763 and labeled with 35S-
methionine/35S cysteine for 48 hours. Data are averages of 35S incorporation 
from at least 5 independent determinations from two separate cardiomyocyte 
litters ± S.E. 
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Number Name RefSeq Forward Primer Name Forward Primer Sequence Reverse Primer Name Reverse Primer Sequence
1 Abra NM_175844 rat_Abra_642F GCACTCCCAGGCAAACAGATAC rat_Abra_753R TATGTGTTCATCGGCCCACTG
2 Acta1 NM_019212 Acta1_rat-789F CTTCCAGCCTTCCTTTATCGGT Acta1_rat-890R GCGTACAGGTCCTTCCTGATGT
3 Adprhl1 NM_001013054 rat_Adprhl1_491F ACCATCCTACAGGTTTCCTCGG rat_Adprhl1_594R CACCTTCAGCATGTCTCTTCCC
4 ANP (Nppa) NM_012612 ANP (Nppa)-rat-35F TCTTCCTGGCCTTTTGGCT ANP (Nppa)-rat-139R CCAGGTGGTCTAGCAGGTTCTT
5 Apold1 n2 NM_001003403 rat_Apold1_623F CTGGTGCCCTGGATGAACTTAG rat_Apold1_733R ACAACGCTGCATCCAGATCAG
6 Arc NM_019361 rat_Arc_2019F AAGAAAAGCAGACTTCGGCTCC rat_Arc_2146R TGAGACCTGGTGTCGTTCTCCT
7 Areg NM_017123 rat_Areg_51F CTTAGGCTCAGGCCATTATGCA rat_Areg_152R ACCACAAGTCCACCAGCACTGT
8 Arid5a NM_001034934 rat_Arid5a_77F CGGACCAGACCACATCAGAAA rat_Arid5a_218R CAGCTATTAGCACCCAGGAACG
9 Arl5b NM_001015031 rat_Arl5b_219F TCTGAGGTCATCCTGGAACACC rat_Arl5b_353R TAGTGTGTGACCTCGTGAGCCA
10 Arrdc3 NM_001007797 rat_arrdc3_1025F GACCTGAAGCACCACCCAGTTA rat_Arrdc3_1141R CGAACAGTGGTCCTTGAAGAGC
11 Atf3 NM_012912 rat_Atf3_239F AGGTGGCCCCTGAAGAAGATGA rat_Atf3_358R TCTCTGACTCCTTCTGCAGGCA
12 Atp8b1 NM_001106140 rat_Atp8b1_538F GTCATTAAGGACGGCAGGTTCA rat_Atp8b1_640R GCAGAATGTCGGCTGGAATAAA
13 Axud1 NM_001108786 rat_Axud1_763F AAATGCCAGATGGATCACACG rat_Axud1_864R TGTCTGAACTCTCGCCTGATTG
14 B3gnt2 n2 NM_001107140 rat_B3gnt2_386F CGCTGCTCATAGATCAACCGA rat_B3gnt2_488R TCCCGAATTGCTTGCCTTC
15 Bhlhb2 NM_053328 rat_Bhlhb2_683F AGAGCGGTTTACAAGCTGGTGA rat_Bhlhb2_799R CATGCTTGGCCAGGTACTGAA
16 BNP (Nppb) NM_031545 BNP (Nppb)-rat-44F TTTTCCTTAATCTGTCGCCGC BNP (Nppb)-rat-144R TATCAGCGCCAGCAGCTTCTGC
17 Btg2 NM_017259 rat_Btg2_51F AGGTTTCCTCACCAGTCTCCTG rat_Btg2_152R TGTAATGATCGGTCAGTGCGTC
18 Cbr3 NM_001107110 rat_Cbr3_288F AATGGATGATCCAACGCCCT rat_Cbr3_433R TTAACCCCTGCAGACTGCTGAC
19 Ccl7 NM_001007612 rat_Ccl7_91F TCCACTTGCTGCTATGTCAAGA rat_Ccl7_194R TTGAAGATAACAGCTTCCCAGG
20 Ccrn4l NM_138526 rat_Ccrn4l_431F AGTGGAACATCCTCGCTCAAG rat_Ccrn4l_531R CAGGATAAGGCATTTCCTCTCC
21 Cd24 n2 NM_012752 rat_Cd24_841F AGTCCCACGTCGTTGACCTCTA rat_Cd24_960R CCTGGCCCGTGTCAATTACTAA
22 Cd55 n2 NM_022269 rat_Cd55_950F CCCCACTGTCTCATAAACCCAC rat_Cd55_1055R GGTACATGCTGTGTTGCTGGAA
23 Cebpb NM_024125 rat_Cebpb_1533F ATCCGGATCAAACGTGGCT rat_Cebpb_1637R CCCCGCAGGAACATCTTTAA
24 Ch25h n2 NM_001025415 rat_Ch25h_511F TGGCTACCCAATACATGAGCGT rat_Ch25h_618R CGTGAAAGACGAGGATGGTGAG
25 Cln8 NM_001007686 rat_Cln8_36F CTGAATGCAGGTTGAGGATGG rat_Cln8_202R AAAATGCTCTCCGCAACGC
26 Coq10b NM_001009671 rat_Coq10b_445F CCACATTTGGTAAAGGCCTCTT rat_Coq10b_545R CATGTTCTTGGATAGCCAGGAA
27 Crem n2 NM_001110860 rat_Crem_821F CTTTGCCACAAGGTGTGGTGA rat_Crem_938R GCAGCTTCCCTGTTTTTCATCA
28 Cxcl1 NM_030845 rat_Cxcl1_230F CCCAAACCGAAGTCATAGCCA rat_Cxcl1_373R CGCCATCGGTGCAATCTATCT
29 Cxcr7 n2 NM_053352 rat_Cxcr7_723F ATCCGGTGACCAGGAGAAACA rat_Cxcr7_825R GTCCAGCAGAACCACAAAATGG
30 Dusp4 NM_022199 rat_Dusp4_422F TCTGCCTGCTTAAAGGTGGCT rat_Dusp4_541R CCAAGGACTCATTTGTGCTGG
31 Dusp5 NM_133578 rat_Dusp5_655F TGCACCACCCACCTACACTACA rat_Dusp5_767R CCCTCTTCCCTGACACAGTCAA
32 Egr1 NM_012551 rat_Egr1_1024F CAGTGTCGAATCTGCATGCGTA rat_Egr1_1129R TTCTCCCACAAATGTCACAGGC
33 Egr2 NM_053633 rat_Egr2_163F GCTGGAGATGGCATGATCAAC rat_Egr2_263R TGGTTTCTAGGCGCAGAGATG
34 Egr3 n2 NM_017086 rat_Egr3_995F CCTTTGCCTGTGAGTTCTGTGG rat_Egr3_1101R ACCCCCTTTCTCCGACTTCTTC
35 Epha2 NM_001108977 rat_Epha2_1709F CACACTTACGAAGACCCCAACC rat_Epha2_1809R CCAAACTCTCCTGCTCCAATGA
36 Ephb3 NM_001105868 rat_Ephb3_1608F GACCACGAGTGAAAGAGGCTCA rat_Ephb3_1708R CGACGACCACCATGAAGACAA
37 Errfi1 NM_001014071 rat_Errfi1_1066F TATGTCAGCAGCAAAGCCCTG rat_Errfi1_1171R AATGCGTGGAGCTGACCTTCT
38 Ets2 NM_001107107 rat_Ets2_1029F CAGCAGTTCTGGAAAACCCAAG rat_Ets2_1219R AGGACATGGTCGGCTTACTGAG
39 Fos NM_022197 rat_Fos_F GGAGGACCTTATCTGTGCGTGA rat_Fos_R TTTGCTACATCTCCGGAAGAGG
40 Fosb NM_001013146 rat_Fosb_F GAAGACCCCGAGAAGAAACACT rat_Fosb_R TCCGACGGTTTCTGCATTT
41 Fosl1 NM_012953 rat_Fosl1_411F GGAGACCGACAAGTTGGAGGAT rat_Fosl1_659R  TGCAGTGCTTCCGGTTCAA
42 Foxq1 n2 NM_022858 rat_Foxq1_1155F TTGACAGGAGCTTGGAGCTCTG rat_Foxq1_1278R AAGGTGGAAAGTGCACAGCCCT
43 Gadd45g NM_001077640 rat_Gadd45g_147F CCTGAATGTGGACCCTGACAAT rat_Gadd45g_254R CAGAACGCCTGGATCAACGTA
44 Gclc NM_012815 rat_Gclc_435F TTCATTTCCCAGGCTAGGCTG rat_Gclc_537R GGCTTCGTCTGGAAAGAAGAGG
45 Gda NM_031776 rat_GDA_201F GCTGAGCCACCATGAGTTCTTC rat_GDA_303R ATCCAAAAGTGGCAGGTCGAC
46 Gem NM_001106637 rat_Gem_498F AGAAGGCGTCTGAGCTGAGGAT rat_Gem_630R GCACAAGCTCTCCCTTCTGACA
47 Gfpt2 NM_001002819 rat_Gfpt2_315F CCCACAGCGTTCAGACAAAGA rat_Gfpt2_418R ACTCGTAGCCCTTGCTTTCCA
48 Gprc5a NM_001079890 rat_Gprc5a_884F GCTATGGTGTGGAGAACAGAGC rat_Gprc5a_997R GGCGATTCTGCATCTGAAAA
49 Grasp n2 NM_138894 rat_Grasp_532F GGCAACGTTCTCAGACTGGAAA rat_Grasp_646R ACCTGTATTCGCCCCACTTCTC
50 Has1 n2 NM_172323 rat_Has1_981F GGCCTGGTACAACCAGAAGT TC rat_Has1_1097R CATCTGGAGCGCGAGGTATACT
51 Has2 n2 NM_013153 rat_Has2_627F GGTGTGTGACTCAGACACCATG rat_Has2_730R TCTGAACATCTCCCCCAACA
52 Hk2 n2 NM_012735 rat_Hk2_1731F CATTGTCCAGTGCATTGCG rat_Hk2_1843R TGCTCTGGTCTAGGCTGTTCTG
53 Id1 NM_012797 rat_Id1_514F GCACTGAGGAACCAGATGGACT rat_Id1_640R CCTGGACAGATCCGTCAAGAGT
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Supplementary Table 1. Quantitative RT-PCR primers. 
 
 
 
 
 
 
 
54 Id3 NM_013058 rat_Id3_228F CATCCTCGACCTTCAAGTGGTT rat_Id3_334R TGGAGATCACAAGTTCCGGAGT
55 Id4 n2 NM_075582 rat_Id4_202F ATGAACGACTGCTACACTCGCC rat_Id4_313R GCAGGTCCAGGATGTAGTCGAT
56 Ier2 n2 NM_001009541 rat_Ier2_36F AACGCCGGTCTTAATCCATTGT rat_Ier2_136R CCACACGGACAGTGTCATGATG
57 Ier3 NM_212505 rat_Ier3_285F AGGATCCTCTTTCTCCTGCTCG rat_Ier3_389R TGATATGGCGCTGGTAGCATC
58 Il4ra NM_133380 rat_Il4ra_657F CACGTGGTACAACCACTTCCA rat_Il4ra_762R GCTGAAGTAACAGGTCAGGCAA
59 IL6 NM_012589 rat_IL6_93F GATACCACCCACAACAGACCAG rat_IL6_197R GCCATTGCACAACTCTTTTCTC
60 IL10 NM_012854 rat_IL10_375F CTGTCATCGATTTCTCCCCTG rat_IL10_486R GTCAAACTCATTCATGGCCTTG
61 Irs2 NM_001168633 rat_Irs2_3968F CCGTGGTGAAAGAGTAAAGTGC rat_Irs2_4096R AGAATTGCTCCCGTTGGAAG
62 Itpkc NM_178094 rat_Itpkc_1643F GGATTGAAGGCATCAAGAAGGC rat_Itpkc_1747R CCCCATTCACAAAGTCTTCCAA
63 JunB NM_021836 rat_JunB_376F AAACCCACCTTAGCGCTCAAC rat_JunB_512R TTCAGAGATGCGCCTGTGTCT
64 Klf4 NM_053713 rat_Klf4_1098F CCATTATCAAGAGCTCATGCCA rat_Klf4_1225R TTTTGCCACAGCCTGCATAG
65 Klf5 n3 NM_053394 rat_Klf5_525F GCTGGTCCAGACAAGATGTGA rat_Klf5_760R TCTTGATCTGTGTTACGCATGG
66 Klf10 NM_031135 rat_Klf10_18F TTCTCTCCAGCAAGCTTCGGA rat_Klf10_130R GCGCTTCCACAGCTTCAAAGT
67 Lif NM_022196 rat_Lif_259F ACGGATTTCCCACCTTTCCA rat_Lif_367R GATCCCAGGTGATGTTGGTCAG
68 Lmod2 n2 NM_001100964 rat_Lmod2_169F GAGAAAACCCCAACCGGAAAC rat_Lmod2_279R TGCAAGCTTTCCACATTCCC
69 Maff n2 NM_001130573 rat_Maff_611F GAACCCACTCCCGTCCTAAAGA rat_Maff_715R TAGAGCCCAGGAAAGGAATGTG
70 Mafk NM_145673 rat_Mafk_18F GCCCAACAAGACATTGAAGGTC rat_Mafk_158R TTCAGCCGAGTTACCTCCTCCT
71 Mgat3 NM_019239 rat_Mgat3_46F CCTTGGATGAAGATGAGACGCT rat_Mgat3_213R GGCATTGTTCCAGAAGAAGCTG
72 Myc NM_012603 rat_Myc_680F ATTCCACGGCCTTCTCTTCTTC rat_Myc_806R TCTTCTTCAGAGTCGCTGCTGG
73 Nab2 NM_001134874 rat_Nab2_851F TGGATGATAACGACAGCCAGAA rat_Nab2_964R TGGTCAACTCGTGCAAGCTAAG
74 Nap1l5 n2 NM_001044293 rat_Nap1l5_439F AAGATCCAGGAACTCACCGGAG rat_Nap1l5_610R AGTCTGTCAGCTGCTGTGCTCA
75 Nfil3 NM_053727 rat_Nfil3_120F TGGCAACCTTGGATAACCCATA rat_Nfil3_252R GGAGACGAATCACTTCCCCAGT
76 Nfkbiz NM_001107095 rat_Nfkbiz_796F GTGGAGGCGAAGGATCGTAAA rat_Nfkbiz_896R CAACTCGGCAACTCCAAAAAGA
77 Nid67 NM_173126 rat_Nid67_1084F CCAGTGTCGAAAAGTTGGCAA rat_Nid67_1188R AAAACTCAGCCGCCCTGAA
78 NR4A1 NM_024388 rat_NR4A1_1538F CGGCTTTGGTGACTGGATAGAC rat_NR4A1_1657R CCATGTCGATCAGTGATGAGGA
79 NR4A2 NM_019328 rat_NR4A2_1192F AGCGCACGGTGCAAAAAA rat_NR4A2_1301R CAGGCACTTCTGAAACCGACA
80 NR4A3 NM_031628 rat_NR4A3_1699F GCAAATAAAAACTGCCCGGTAG rat_NR4A3_1799R CGCACAACTTCCTTCACCATC
81 Nuak2 NM_001007617 rat_Nuak2_351F TGCCATCCATGAAGTGTTTGAG rat_Nuak2_495R GGACACGATCTGTCGGAAGAAA
82 Olr1 NM_133306 rat_Olr1_862F TCCACCTCCCCATTTTGGAT rat_Olr1_967R CGCCCCTGGTCCTAAAGAATT
83 Pde4b NM_017031 rat_Pde4b_1151F ACCATTCTGATGTGGCGTATCA rat_Pde4b_1251R TGTGAAGACAGCATCCAGTGCT
84 Per1 NM_001034125 rat_Per1_2124F CAATAAGGCAGAGAGCGTGGTG rat_Per1_2227R TCATGATGATGTCCGACTCCG
85 Phlda1 NM_017180 rat_Phlda1_468F AGGAGTGCTGGAAAAGCGAAG rat_phlda1_581R TGCTGATGTTGTACCTGCTTGG
86 Pim1 NM_017034 rat_Pim1_591F CTACACGGACTTTGACGGAACC rat_Pim1_705R CATGTCATAGAGCAGGATCCCC
87 Plat NM_013151 rat_Plat_523F TACTGCAGAAACCCAGACCGAG rat_Plat_640R AGCAGTCCTCAGTTGGTCCCTT
88 Plaur NM_134352 rat_Plaur_F ACAGGACCATGAGCTACCGC rat_Plaur_R TCTCGGTGAGGCTGACGATC
89 Plk3 NM_022187 rat_Plk3_222F TCGCTGCTATGAAGCCACTGA rat_Plk3_328R CGTTTATGATCTTCTCGCGCTG
90 Plscr1 NM_057194 n/a n/a n/a n/a
91 Ppp1r15a NM_133546 rat_Ppp1r15a_1245F GGTGGCCTTCTATTTACCTGGA rat_Ppp1r15a_1390R GCACCTTTCTACCCTTCAGAGG
92 Rgs2 NM_053453 rat_Rgs2_433F CGAGAAGGAAGCTCCCAAAGAG rat_Rgs2_560R TCTCCATCAGGCTGTACACCCT
93 Rhob NM_022542 rat_Rhob_229F ACCGACGTCATCCTTATGTGCT rat_Rhob_360R GTCTTTTTTGTTGGCCACCAAG
94 Rnd1 n2 NM_001013222 rat_Rnd1_90F ACAGGTGCTAGCGAAAGACTGC rat_Rnd1_213R AGAGCCTGAGGTATCCCAGAGA
95 S1pr1 NM_017301 rat_S1pr1_1234F CTCCGCTGGCAAATTCAAGA rat_S1pr1_1344R ATGGTCTCTGGATTGTCCCCA
96 Serpinb1a NM_001031642 rat_Serpinb1a_415F CAAACCGAAGGTAAAATCCCAG rat_Serpinb1a_525R GAATTTCTCCTCCCACATCCC
97 Slc2a3 NM_017102 rat_Slc2a3_499F CTTGTGGCTCAGGTCTTTGGTT rat_Slc2a3_599R GCGCTCTGTAGGATAGCTGGAA
98 Slc25a25 n2 NM_145677 rat_Slc25a25_152F GGAAGCAGAAAATTGTGCAAGC rat_Slc25a25_298R CATCGATTCGCCCATCATTC
99 Snai1 NM_053805 rat_Snai1_603F CCACACTGGTGAGAAGCCTTTC rat_Snai1_760R GTTTGTGGAGCAAGGACATTCG
100 Snf1lk NM_021693 rat_Snf1lk_1240F AGTTCGCTTCAGCCCTTATTCT rat_Snf1lk_1346R TCCTCACTGATAGCTGTGTCCA
101 Thbd n2 NM_031771 rat_Thbd_1415F CAAGCTTTTGTCAATGCCCTGA rat_Thbd_1515R ACATTCATTGGTGAGGCATTCG
102 Tmem100 n2 NM_001017479 rat_Tmem100_146F CTGCCTTTTTGTGAGCTTCCAC rat_Tmem100_305R GGCTTTTCTCCATTGTCACAGG
103 Trib1 NM_023985 rat_Trib1_426F CATTACTGGCATCGTGGAAGTG rat_Trib1_527R CTTTTCCGGCTTCGTACATAGG
104 Ugdh NM_031325 rat_Ugdh_146F CGCTTCCTATTTATGAGCCTGG rat_Ugdh_249R ATCGGCTTCTCTGATGGCATC
105 Zc3h12a NM_001077671 rat_Zc3h12a_351F GCCTTCCACTGTAGAACCCTCA rat_Zc3h12a_455R TTGTTCCCATGGCTCATGG
106 Zfp36 NM_133290 rat_Zfp36_30F TGCCATCTACGAGAGCCTTATG rat_Zfp36_285R TGCAGTAGGCGAAGTAGGTGAG
107 Zfp36l2 NM_001036626 rat_Zfp36l2_2F TGTCGACCACTCTTCTGTCAGC rat_Zfp36l2_104R GCCTTCTTGTCCAGCATGTTG
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Supplementary Table 2. ChIP RT-PCR primers. The "Predicted Site Position" 
column denotes multiple predicted binding sites in one gene where applicable. 
The "Sites Covered" column, in turn, refers to those sites that are too close to be 
distinguished from one another (typically <250 nucleotides away from each other, 
the approximate resolution of the ChIP experiment), and therefore both (or, in 
some cases, three or four sites) are tested with one primer set. 
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Supplementary Table 3. RT-PCR validation of the microarray results. 
Independent total RNA samples for microarray hybridizations were tested in 
parallel with quantitative RT-PCR. PCR primers for GAPDH mRNA were used to 
normalize the amount of RNA and the relative RNA transcript levels between 
treated and untreated samples.     
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Supplementary Table 4. Complete TRANSFAC output of statistically 
overrepresented transcription factors (non-overlapping sites, done under MATCH 
minSUM thresholds). Set 1: new list of SB-216763 induced genes in NRVMs; 
greater than 0.8 (log 2 scale) induction by SB-216763, also induced by 
phenylephrine; >50% in Set 1 and <1 hit per kb in Set 2 (background set). Set 2: 
logFC of >-0.005 and <0.005; phenylephrine versus NT on Affymetrix Rat Gene 
1.0 ST arrays, n=3; only those with NCBI RefSeqs were included; 659 submitted. 
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CHAPTER THREE – FUTURE DIRECTIONS 
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Further work that is needed for this research is the siRNA knockdown of our 
gene subset to confirm their induction after stimulation with phenylephrine. We 
would need to develop an effective viral transduction method as cardiomyocytes 
are difficult to transfect in vitro with nonviral methods. Essentially, a passive 
method does not work because the cardiomyocytes do not actively take up 
materials from their surrounding environment. Djurovic et al. tested nonviral vs. 
viral methods and concluded that viral methods were the most efficient. They did 
make the claim that nonviral methods could be a useful alternative, but this claim 
was based on a 7-8% transfection rate as compared to the 88% transduction rate 
of their adenoviral method. 
 
Because signaling does not appear to be through the canonical PI3K/Akt/GSK3 
pathway, effort needs to be given towards discovering how GSK3 is being 
regulated in heart cells. In Frey and Olson’s review, they mentioned a paper (Haq 
et al. 2000) in which it was reported that phenylephrine regulates GSK3 in a PI3K 
dependent manner. This directly contradicts our results. When performing our 
microarray analysis, we expanded our focus because very few of the genes that 
were induced by phenylephrine were sensitive to PI3K inhibition by LY294002. 
While our focus was to discover a subset of genes under the control of GSK3 in 
the context of cardiac hypertrophy, it would be interesting to work out this 
contradiction as it would further our understanding of the molecular workings of 
this potentially fatal condition. Other candidates are the Wnt/β-catenin, 
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mTOR/S6K, PKA, PKC, and classical MAPK pathways, all of which negatively 
regulate GSK3 (Niehrs 2012, Jope and Johnson 2004, Cohen and Frame 2001) 
and many of which are linked to cardiac hypertrophy (Frey and Olson 2003). A 
simple set of experiments employing specific kinase inhibitors, RT-PCR, and 
Western blots should uncover at least one way in which GSK3 is regulated in the 
context of cardiac hypertrophy.  
 
Two other areas to explore are the miRNAs and downregulated genes that 
popped up in our microarray analysis. As mentioned before, targeted knockdown 
of either miR-133a or miR-1 will cause hypertrophy (Care et al. 2007). We could 
test whether the silencing of one or both of these miRNAs causes the 
upregulation of the gene subset that we discovered. Conversely, we could also 
overexpress these miRNAs and see if they block expression of our gene subset. 
Among the downregulated genes are Pik3ip1, Bambi, and Znf569. Pik3ip1, 
phosphoinositide-3-kinase interacting protein 1, is a negative regulator of PI3K; 
Bambi, BMP and activin membrane-bound inhibitor, is involved in the TGFβ 
signaling pathway; and Znf569, also known as Zfp74 (zinc finger protein 74), is 
another zinc finger involved in transcription regulation. It would also be highly 
useful and revealing for therapeutic purposes to test knockdown of our gene 
subset in an in vivo mouse model. 
 
	  	  
39	  
There were several other transcription factors that came up in our computational 
analysis and only 8 of the 12 genes were CREB-mediated. ChIP analysis of the 
other transcription factors would delineate how the other 4 are regulated as well 
as if the initial 8 genes are alternatively regulated. The genes that are mediated 
by two or more transcription factors would make better candidates for therapeutic 
targets since tighter regulations could be an indicator of greater significance 
within the cell. AP-1 (activator protein 1) actually consists of Fos and Jun dimers 
and has been linked to cell transformation, proliferation, differentiation, and 
apoptosis (Ameyar et al. 2003). NFκB (nuclear factor kappa B) is another protein 
complex that is most commonly associated with immune and inflammatory 
responses but has also been linked to apoptosis and cell survival (Dutta et al. 
2006). Forkhead transcription factors (e.g. FOXO1, FOXO3, FOXO4, FOXO6) 
are involved in development, differentiation, proliferation, apoptosis, stress 
resistance, and metabolism (van der Horst and Burgering 2007, Carlsson and 
Mahlapuu 2002). MEF2 (myocyte enhancer factor 2) has roles in differentiation, 
proliferation, morphogenesis, organogenesis, survival, and apoptosis (Potthoff 
and Olson 2007). NFAT (nuclear factor of activated T cells), as its name denotes, 
was first discovered in T cells, but further research has connected it to cell fate 
determination, embryonic development, and organogenesis (Macian 2005, Qin et 
al. 2014). In particular, MEF2 and NFAT have been implicated in cardiac 
hypertrophy (Frey and Olson 2003). 
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We had used an in vitro phenylephrine model of inducing cardiac hypertrophy in 
our study. We could also apply the same approach and methods in an in vitro 
isoproterenol (another name for isoprenaline) model with the purpose of 
comparing and contrasting an α-adrenergic approach (phenylephrine) with a β-
adrenergic one (isoproterenol). This global bird’s eye view could reveal more 
hypertrophic genes that were not uncovered by the α-adrenergic approach and 
highlight overlapping gene targets, which would be more effective therapeutically 
since they could be crossing multiple molecular pathways. We can also compare 
the levels of induction of any overlapping results. This is also an opportunity to 
apply RNA-seq technology to more efficiently undertake this global approach. 
 
Finally, when thinking about how to move forward in this area of research, 
potential side effects need to be considered. One way to gauge the sphere of 
potential side effects is to take a look from the perspective of signaling cascades 
as we have done. The impact of treatment becomes more limited as one goes 
further down a signaling pathway, but the extent of the side effects becomes 
smaller as well. Grasping the big picture has become a recent trend in how 
research is being conducted and is a powerful way of putting all the pieces 
together and teasing apart the unique features of what one is studying. Thus, 
considering what we know about cardiac hypertrophy, taking a global system-
wide viewpoint may enhance our understanding of what occurs in this disease 
and help direct the best possible way to treat it. 
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• Managed a team of stock leaders who maintained the different genetic lines 
of fruit flies in the lab 
• Ordered lab supplies and organized lab inventory 
 
Publications 
 
Tullai, J. W., Moss, M. E., Sepulveda, S. M., Brennan, J. F., Naya, F. J., Cooper, 
G. M. Role of GSK-3 in CREB-mediated transcription regulation, hypertrophy and 
survival in cardiomyocytes. (in preparation) 
	  
Terragni, J., Nayak, G., Banerjee, S., Medrano, J., Graham, J. R., Brennan, J. F., 
Sepulveda, S., and Cooper, G. M. (2011). The E-box Binding Factors Max/Mnt, 
MITF, and USF1 Act Coordinately with FoxO to Regulate Expression of 
Proapoptotic and Cell Cycle Control Genes by Phosphatidylinositol 3-
Kinase/Akt/Glycogen Synthase Kinase 3 Signaling. J. Biol. Chem. 286, 36215-
36227. 
 
Sepulveda, S., Shojaeian, P., Rauser, C. L., Jafari, M., Mueller, L. D., Rose, M. 
R. (2008). Interactions between injury, stress resistance, reproduction, and aging 
in Drosophila melanogaster. Exp. Gerontol. 43, 136-145. 
 
Selected Undergraduate Research Presentations 
 
“Injury, Stress, and Aging” 
Oral presenter at the 2005 California Alliance for Minority Participation (CAMP) 
Statewide Undergraduate Research Symposium 
UC Irvine, February 25-27 
 
“The Effects of Injury on the Mortality of Drosophila melanogaster” 
Poster presenter at the 2005 Society for Advancement of Chicanos and Native 
Americans in Science (SACNAS) Undergraduate Research Symposium 
Denver, CO, September 29-October 2 
 
“The Effects of Injury on the Aging and Fecundity of Drosophila melanogaster” 
Poster presenter at the 2006 Annual Biomedical Research Program for Minority 
Students (ABRCMS) Symposium 
Anaheim, CA, November 8-11 
 
“The Effects of Injury on the Aging and Fecundity of Drosophila melanogaster” 
Poster presenter at the 2007 American Association for the Advancement of 
Science (AAAS) Research Symposium 
San Francisco, CA, February 15-18 
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Awards and Honors 
 
Merit bonuses for exceptional performance evaluations, resulting in hourly 
performance increases on 1/1/2010, 1/1/2011, and 7/1/2012 
 
Accepted into the Minority Access to Research Careers (MARC) training 
program, funded by the National Institutes of Health (NIH), 2005-2007 
 
Excellence in Research – UC Irvine 2007 
 
Sigma Xi member, 2006-2007 
 
Funded by Amgen for the 2007 AAAS Undergraduate Research Symposium 
 
 
